5-HT4 receptor antagonists

ABSTRACT

Compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:  
     X—CO—CH 2 —Z  (I)  
     wherein  
     X is a monocyclic or polycyclic aromatic group,  
     Z is of sub-formula (h),(j) or (k):  
                 
 
     wherein  
     n 1  is, 2,3 or 4; n 2 is 0,1,2,3 or 4; n 3  is 2,3,4 or 5;  
     q is 0,1,2 or 3; p is 0,1 or 2; m is 0,1 or 2;  
     R 5  is hydrogen, C 1-12 alkyl, aralkyl or R 5  is (CH 2 ) z —R 10  wherein z is 2 or 3 and R 10  is selected from cyano, hydroxyl, C 1-6  alkoxy, phenoxy, C(O)C 1-6  alkyl, COC 6 H 5 , —CONR 11 R 12 , NR 11 COR 12 , SO 2 NR 11 R 12  or NR 11 SO 2 NR 11 R 12  or NR 11 SO 2 R 12  wherein R 11  and R 12  are hydrogen or C 1-6  alkyl; or R 5  is straight or branched chain alkylene of chain length 1-6 carbon atoms terminally substituted by aryl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered fused bicyclic heteroaryl linked through carbon, C 2-7  alkoxycarbonyl, or secondary or tertiary hydroxy substituted C 1-6  alkyl; ; and  
     R 6 , R 7  and R 8  are independently hydrogen or C 1-6  alkyl; and  
     R 9  is hydrogen or C 1-10  alkyl;  
     and their use as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders.

5-HT4 RECEPTOR ANTAGONISTS

[0001] This is a divisional of Application No. 08/553,390, filed Nov. 22, 1995.

[0002] This invention relates to novel compounds having pharmacological activity, to a process for their preparation and to their use as pharmaceuticals.

[0003] European Journal of Pharmacology 146 (1988), 187-188, and Naunyn-Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410, describe a non classical 5-hydroxytryptamine receptor, now designated the 5-HT₄ receptor, and that ICS 205-930, which is also a 5-HT₃ receptor antagonist, acts as an antagonist at this receptor.

[0004] WO 91/16045 (SmithKline and French Laboratories Limited) describes the use of cardiac 5-HT₄ receptor antagonists in the treatment of atrial arrhythmias and stroke.

[0005] EP-A-501322 (Glaxo Group Limited), WO 93/02677, WO 93/03725, WO 93/05038, WO 93/05040, WO 93/18036, PCT/EP93/03054, PCT/GB93/01895, PCT/GB93/02028, PCT/EP93/02808, PCT/EP93/02775, PCT/EP93/02809, PCT/GB93/02130, PCT/EP93/003054, PCT/GB94/000172 (SmithKline Beecham plc) describe compounds having 5-HT₄ receptor antagonist activity.

[0006] It has now been discovered that certain novel compounds also have 5-HT₄ receptor antagonist properties.

[0007] Accordingly, the present invention provides a compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

X—CO—CH₂—Z  (I)

[0008] X is a monocyclic or polycyclic aromatic group, such as a group of formula (a), (b), (c), (d), (e), (f) or (g):

[0009] wherein p0 L is N or CR_(S) wherein R_(s) is hydrogen, C₁₋₆ alkoxy, halogen, C₁₋₄ alkyl or cyano;

[0010] Q is NR₁ ^(a), CH₂, O or S;

[0011] W is CH or N;

[0012] X₁-(CH₂)_(x)—X₂ forms a 5-7 membered ring wherein X₁ is O or S; X₂ is O, S, —CH₂—, NR or NRCO wherein R is hydrogen or C₁₋₆ alkyl; and

[0013] x is 1,2 or 3;

[0014] one of X₃ and X₄ is N and the other is C; and

[0015] X₅ is N or CR¹ wherein R¹ is hydrogen, C₁₋₆ alkoxy, halo, C₁₋₆ alkyl or cyano;

[0016] R₁ ^(a) is hydrogen, C₁₋₁₀ alkyl, C₂₋₆ alkenyl, aralkyl, C₂₋₆ alkanoyl or C₂₋₆ alkanoyl C₁₋₃ alkyl;

[0017] R₃ ^(a) is hydrogen, halo, C₁₋₆ alkyl, amino, nitro or C₁₋alkoxy;

[0018] R₄ ^(a) is hydrogen, halo, C₁₋₆ alkyl or C₁₋₆ alkoxy;

[0019] R₁ ^(b) is C₁₋₆ alkoxy; and

[0020] R₂ ^(b) is hydrogen, chloro or fluoro;

[0021] R₃ ^(b) is hydrogen, C₁₋₆ alkyl, amino optionally substituted by a C₁₋₆ alkyl group, halo, hydroxy or C₁₋₆ alkoxy;

[0022] R₄ ^(b) is hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, amino or C₁₋₆ alkylthio; and

[0023] R₅ ^(b) is hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy or amino;

[0024] R_(c) is hydrogen, C₁₋₆ alkoxy, halo or C₁₋₆ alkyl;

[0025] R₁ ^(d) is hydrogen, amino, halo, C₁₋₆ alkyl, hydroxy or C₁₋₆ alkoxy;

[0026] R₂ ^(d) is hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, amino or C₁₋₆ alkylthio;

[0027] R₃ ^(d) is hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy or amino;

[0028] R₄ ^(d) and R₅ ^(d) are independently hydrogen or C₁₋₆ alkyl;

[0029] R₁ ^(e) is hydrogen, halogen, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulphonyl, C₁₋₆ alkylsulphinyl, C₁₋₇ acyl, cyano, C₁₋₆ alkoxycarbonyl, C₁₋₇ acylamino, hydroxy, nitro or amino, aminocarbonyl, or aminosulphonyl, optionally N-substituted by one or two groups selected from C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and C₃₋₈ cycloalkyl C₁₋₄ alkyl or disubstituted by C₄ or C₅ polymethylene; phenyl or phenyl C₁₋₄ alkyl group optionally substituted in the phenyl ring by one or two of halogen, C₁₋₆ alkoxy or C₁₋₆ alkyl groups;

[0030] R₃ ^(e) is hydrogen, halo, C₁₋₆ alkyl, amino, nitro or C₁₋₆ alkyl;

[0031] R₄ ^(e) is hydrogen, halo, C₁₋₆ alkyl or C₁₋₆ alkoxy;

[0032] X₆—X₇ is NR_(Z)—CO or CR₁ ^(f)R₂ ^(f)—CR₃ ^(f)R₄ ^(f) where

[0033] R_(z) and R₁ ^(f) to R₄ ^(f) are independently hydrogen or C₁₋₆ alkyl; and/or

[0034] R₁ ^(f)/R₂ ^(f) and R₃ ^(f)/R₄ ^(f) together are a bond and/or R₁ ^(f)/R₂ ^(f)/R₃ ^(f)/R₄ ^(f) are joined to form C₃₋₆ polymethylene;

[0035] R_(a) ^(f) is hydrogen, halo, C₁₋₆ alkyl, amino, nitro or C₁₋₆ alkyl;

[0036] R_(b) ^(f) is hydrogen, halo, C₁₋₆ alkyl or C₁₋₆ alkoxy;

[0037] Xg is O, S, SO, SO₂, CH₂, CH, N or NR wherein R is hydrogen or C₁₋₆ alkyl;

[0038] A is a saturated or unsaturated polymethylene chain of 2-4 carbon atoms;

[0039] R₁ ^(g) and R₂ ^(g) are hydrogen or C₁₋₆ alkyl;

[0040] R₃ ^(g) is hydrogen, halo, C₁₋₆ alkyl, amino, nitro or C₁₋₆ alkoxy;

[0041] R₄ ^(g) is hydrogen, halo, C₁₋₆ alkyl or C₁₋₆ alkoxy;

[0042] Z is of sub-formula (h),(j) or (k):

[0043] wherein

[0044] n¹ is 1,2,3or 4;n²is 0,1,2,3or4; n³ is 2,3,4 or 5;

[0045] q is 0,1,2 or 3; p is 0,1 or 2;m is 0,1 or2;

[0046] R₅ is hydrogen, C₁₋₁₂ alkyl, aralkyl or R₅ is (CH₂)_(Z)—R₁₀ wherein z is 2 or 3 and R₁₀ is selected from cyano, hydroxyl, C₁₋₆ alkoxy, phenoxy, C(O)C₁₋₆ alkyl, COC₆H₅, —CONR₁₁R₁₂, NR₁₁COR₁₂, SO₂NR₁₁R₁₂ or NR₁₁SO₂R₁₂ wherein R₁₁ and R₁₂ are hydrogen or C₁₋₆ alkyl; or R₅ is straight or branched chain alkylene of chain length 1-6 carbon atoms terminally substituted by aryl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered fused bicyclic heteroaryl linked through carbon, C₂₋₇ alkoxycarbonyl, or secondary or tertiary hydroxy substituted C₁₋₆ alkyl;; and

[0047] R₆, R₇ and R₈ are independently hydrogen or C₁₋₆ alkyl; and

[0048] R₉ is hydrogen or C₁₋₁₀ alkyl;

[0049] having 5-HT₄ receptor antagonist activity.

[0050] Examples of alkyl or alkyl containing groups include C₁, C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁ or C₁₂ branched, straight chained or cyclic alkyl, as appropriate. C₁₋₄ alkyl groups include methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl. Cyclic alkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl optionally substituted by one of more alkyl groups of up to 4 carbon atoms.

[0051] Aryl includes phenyl and naphthyl optionally substituted by one or more substituents selected from halo, C₁₋₆ alkyl and C₁₋₆ alkoxy.

[0052] Values for monocyclic heteroaryl include pyridyl, pyrimidyl, pyrazinyl, pyrryl, imidazolyl, thienyl, furanyl, oxazole or thiazole (all possible isomers). Bicyclic heteroaryl include benzofuranyl, benzothiophenyl, indolyl and indazolyl, quinolyl and isoquinolyl (all possible isomers).

[0053] Values for 3 to 8 membered heterocyclyl, include cyclic polymethylene interrupted by one or two of N, O or S, linked through C or N, for example N-linked piperidinyl or pyrrolidinyl.

[0054] Halo includes fluoro, chloro, bromo and iodo, preferably chloro.

[0055] L in formula (a) is favourably C—H, C—CH₃, C—Cl or C—OCH₃.

[0056] Q in formula (a) is favourably NR₁ ^(a).

[0057] R₁ ^(a) is preferably hydrogen or a methyl or ethyl group.

[0058] R₁ ^(b) is preferably methoxy.

[0059] R₃ ^(b) is preferably amino.

[0060] R₄ ^(b) is preferably halo.

[0061] R₅ ^(b) is preferably hydrogen.

[0062] A substituent when halo is selected from fluoro, chloro, bromo and iodo. R₄ ^(a) when halo is preferably iodo.

[0063] Suitable examples of the X₁—(CH₂)_(x)—X₂ moiety include O—(CH₂)₂—O, O—(CH₂)₃—O, O—CH₂—O, O—(CH₂)₂—NR, O—(CH₂)₂—S or O—CH₂—CONR, wherein any of the methylene linkages are optionally mono- or di- substituted by C₁₋₆ alkyl groups, such as methyl. Preferably X₁—(CH₂)₂—X₂ is O—(CH₂)₂—O Further suitable examples of X₁—(CH₂)_(x)—X₂ include O—(CH₂)₂—CH₂, O—(CH₂)₃—CH₂, O—CH₂—CH₂, or corresponding values wherein X₁=X₂=CH₂, wherein any of the methylene linkages are optionally mono- or di-substituted by C₁₋₆ alkyl groups, such as methyl. Preferably such X₁—(CH₂)₂—X₂ is O—(CH₂)₂—CH₂.

[0064] R₁ ^(d) is preferably hydrogen or amino.

[0065] R₂ ^(d) is preferably hydrogen or halo.

[0066] R₃ ^(d) is preferably hydrogen or halo.

[0067] R₄ ^(d) and R₅ ^(d) are often hydrogen. When R₄ ^(d) or R₅ ^(d) is C₁₋₆ alkyl, it is often methyl.

[0068] R₁ ^(e) is preferably CF₃ or an ethyl group.

[0069] X₅ is preferably N, C—H or C—OCH₃;

[0070] R₃ ^(e) is preferably hydrogen.

[0071] R₄ ^(e) is preferably hydrogen or halo, such as iodo.

[0072] Suitable examples of X₆—X₇ when CR₁ ^(f)R₂ ^(f)—CR₃ ^(f)R₄ ^(f) include CH₂—CH₂ and CH═CH. X₆—X₇ is preferably NR_(Z)—CO, however, such as NH—CO or NEt—CO.

[0073] R_(a) ^(f) is preferably hydrogen.

[0074] R_(b) ^(f) is preferably hydrogen or halo, such as iodo.

[0075] Values for A include —CH₂—(CH₂)r—CH₂- wherein r is 0,1 or 2;—CH₂—CH═CH—; —C(CH₃)=CH—or when Xg is CH or N, A may be —(CH₂)₂—CH═or —CH═CH—CH═. Other examples of A are as described in the aforementioned patent publications.

[0076] R₁ ^(g) and R₂ ^(g) are often hydrogen or R₁ ^(g) and R₂ ^(g) are gem-dimethyl.

[0077] r is often 1.

[0078] R₃ ^(g) is preferably hydrogen.

[0079] R₄ ^(g) is preferably hydrogen or halo, such as fluoro.

[0080] Other suitable values of X are as described in PCT/GB93/020208, PCT/EP93/02808, PCT/EP93/02775, PCT/EP93/02809, PCT//GB93/02130, PCT/GB94/00172 (all in the name of SmithKline Beecham plc).

[0081] When Z is of sub-formula (h), n¹ is preferably 2,3 or 4 when the azacycle is attached at the nitrogen atom and n1 is preferably 1 when the azacycle is attached at a carbon atom, such as the 4-position when q is 2.

[0082] When Z is of sub-formula (j), n² is preferably such that the number of carbon atoms between the ester or amide linkage is from 2 to 4 carbon atoms.

[0083] Suitable values for p and m include p=m=1; p=0, m=1, p=1, m=2 p=2, m=1.

[0084] When Z is of sub-formula (k), n³ is preferably 2,3 or 4.

[0085] R₈ and R₉ are preferably both alkyl, especially one of R₈ and R₉ is C₄ larger alkyl.

[0086] Specific values of Z of particular interest are as follows:

[0087] The invention also provides novel compounds within formula (I) with side chains (i), (ii), (iii), (iv), (v), (vi) or (vii). In a further aspect, the piperidine ring in (i), (ii) or (iii) may be replaced by pyrrolidinyl or azetidinyl, and/or the N-substituent in (i) or (ii) may be replaced by C₃ or larger alkyl or optionally substituted benzyl.

[0088] In an alternative aspect, the N-substituent in formula (i) or (ii) may be replaced by (CH₂)_(n)R₄ as defined in formula (I) of EPA 501322 and in relation to the specific examples of EP-A-501322, or it may be replaced by a substituent as as defined in formula (I) and in relation to the specific examples of in PCT/EP93/03054 (SmithKline Beecham plc).

[0089] The pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, a-keto glutaric, a-glycerophosphoric, and glucose- 1-phosphoric acids.

[0090] Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds R_(X)-T wherein R_(x) is C₁₋₆ alkyl, phenyl—C₁₋₆ alkyl or C₅₋₇ cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of R_(x) include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl. Suitable examples of T include halide such as chloride, bromide and iodide.

[0091] Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.

[0092] The compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever a compound of formula (I) or a salt thereof is herein referred to.

[0093] The compounds of formula (I) may be prepared by conventional methods for forming ketones, such as those described in EP-A-242973 (Glaxo Group Limited) and EP-A-387431 (Beecham Group plc).

[0094] Reference is made to the aforemetioned patent publications in the name of Beecham Group plc in respect of intermediates containing X and Z moieties.

[0095] The compounds of the present invention are 5-HT₄ receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.

[0096] They are of potential interest in the treatment of irritable bowel syndrome (IBS), in particular the diarrhoea aspects of IBS, i.e., these compounds block the ability of 5-HT to stimulate gut motility via activation of enteric neurones. In animal models of IBS, this can be conveniently measured as a reduction of the rate of defaecation. They are also of potential use in the treatment of urinary incontinence which is often associated with IBS.

[0097] They may also be of potential use in other gastrointestinal disorders, such as those associated with upper gut motility, and as antiemetics. In particular, they are of potential use in the treatment of the nausea and gastric symptoms of gastro-oesophageal reflux disease and dyspepsia. Antiemetic activity is determined in known animal models of cytotoxic-agent/radiation induced emesis.

[0098] Specific cardiac 5-HT₄ receptor antagonists which prevent atrial fibrillation and other atrial arrhythmias associated with 5-HT, would also be expected to reduce occurrence of stroke (see A. J. Kaumann 1990, Naumyn-Schmiedeberg's Arch. Pharmacol. 342, 619-622, for appropriate animal test method).

[0099] Anxiolytic activity is likely to be effected via the hippocampus (Dumuis et al 1988, Mol Pharmacol., 34,880-887). Activity can be demonstrated in standard animal models, the social interaction test and the X-maze test.

[0100] Migraine sufferers often undergo situations of anxiety and emotional stress that precede the appearance of headache (Sachs, 1985, Migraine, Pan Books, London). It has also been observed that during and within 48 hours of a migraine attack, cyclic AMP levels are considerably increased in the cerebrospinal fluid (Welch et al., 1976, Headache 16, 160-167). It is believed that a migraine, including the prodomal phase and the associated increased levels of cyclic AMP are related to stimulation of 5-HT₄ receptors, and hence that administration of a 5-HT₄ antagonist is of potential benefit in relieving a migraine attack.

[0101] Other CNS disorders of interest include schizophrenia, Parkinson's disease and Huntingdon's chorea.

[0102] The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0103] Such compositions are prepared by admixture and are usually adapted for enteral such as oral, nasal or rectal, or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, nasal sprays, suppositories, injectable and infusable solutions or suspensions. Orally administrable compositions are preferred, since they are more convenient for general use.

[0104] Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art, for example with an enteric coating.

[0105] Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate.

[0106] Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

[0107] Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.

[0108] The oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

[0109] For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

[0110] Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.

[0111] The invention further provides a method of treatment or prophylaxis of irritable bowel syndrome, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine in mammals, such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.

[0112] An amount effective to treat the disorders hereinbefore described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the mammal. However, a unit dose for a 70 kg adult will normally contain 0.05 to 1000 mg for example 0.5 to 500 mg, of the compound of the invention. Unit doses may be administered once or more than once a day, for example, 2,3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50 mg/kg/day, more usually 0.0002 to 25 mg/kg/day.

[0113] No adverse toxicological effects are indicated within the aforementioned dosage ranges.

[0114] The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of irritable bowel syndrome, gastro-oesophageal reflux disease, dyspepsia, atrial arrhythmias and stroke, anxiety and/or migraine.

[0115] The following Examples illustrates the preparation of compounds of formula (I), and the following Descriptions relate to the preparation of intermediates.

[0116] A preferred compound corresponds to any example, but wherein there is an amino substituent in the 4-position and a chloro substituent in the 5-position of the benzoic acid nucleus depicted in formula (I).

EXAMPLE 1 [X=a), L=CH, Q=NCH₃, R₃a and R₄a=H, Z=(i)]

[0117] a) 1-(1-Methyl-1H-indol-3-yl)-3-(4-pyridyl)-propan-1-one

[0118] The product from Description 1, (0.190 g, 0.540 mmol) was dissolved in trifluoroacetic acid (7 ml), and heated to reflux with stirring. After 4h, the reaction mixture was allowed to cool, was diluted with water and treated with aq. potassium carbonate until basic. The aqueous suspension was then extracted with CHCl₃ (2X). The combined organic layers were then dried (Na₂SO₄), and evaporated under reduced pressure to give an orange solid, which was dried in vacuo (0.101 g). The solid was then dissolved in EtOH (15 ml), treated with 10% PdC, and hydrogenated at atmospheric pressure. After 16h, the reaction mixture was filtered through kieselguhr, evaporated under reduced pressure, and dried in vacuo to give the title compound as a colourless oil (0.100 g, 69%).

[0119]¹H NMR (250 MHz, CDCl₃), δ 8.50 (d, 2H), 8.35 (m, 1H), 7.70 (s, 1H), 7.40-7.10 (m, 5H), 3.84 (s, 3H), 3.15 (m, 4H).

[0120] b) 1-(1-Methyl-1H-indol-3-yl)-3-(1-butylpiperidin-4-yl)propan-1-one

[0121] The product from a) above (0.100 g, 0.379 mmol) was dissolved in acetone (4 ml), and treated with 1-bromobutane (0.122 ml, 1.137 mmol) and the mixture was heated to reflux with stirring. After 3h, a further amount of 1-bromobutane (0.122 ml, 1.137 mmol) was added and reflux continued overnight. More 1-bromobutane was then added (0.244 ml, 2.274 mmol), and reflux continued for a further 8h. The reaction mixture was then evaporated under reduced pressure and the residue dissolved in ethanol (10 ml) and acetic acid (0.5 ml). Platinum (IV) oxide (0.03 g) was then added and the mixture hydrogenated at atmospheric pressure. After 16h, the reaction mixture was filtered through kieselguhr and the filtrate evaporated under reduced pressure and dried in vacuo. The product was then purified by silica-gel chromatography (CH₂Cl₂/10% MeOH as eluant) to give the title compound as a pale yellow oil (0.052 g, 43%) which was converted to its oxalate salt m.pt 124-126° C. (oxalate salt)

[0122]¹H NMR (200 MHz, CDCl₃)-free base-δ 8.38 (m, 1H), 7.80 (s, 1H), 7.32 (m, 3H), 3.90 (s, 3H), 3.20 (d, 2H), 2.90 (t, 2H), 2.58 (t, 2H), 2.28 (t, 2H), 1.90-1.50 (m, 8H), 1.35 (m, 3H), 0.95 (t, 3H).

EXAMPLE 2 [X=(g), Xg=O, A=(CH₂)₃, R₁g, R₂g, R₃g, R₄g=H; Z=(i)]

[0123] a) 1-(3,4-Dihydro-2H-[1,3]oxazino[3,2a]indol-10-yl)-3-hydroxy-3-(4-pyridyl)propan-1-one

[0124] 1.6M n-Butyllithium (1.67 ml, 2.67 mmol) was added to dry THF (12 ml), containing diisopropylamine (0.374 ml, 2.67 mmol) under argon at 0° C. with stirring. After 15 minutes, the mixture was cooled to −78° C., and the product from Description 2 (0.420 g, 2.43 mmol) in dry THF (8 ml) was added slowly. The resulting mixture was then left at −78° C. for 1h, before pyridine-4-carboxaldehyde (0.232 ml, 2.43 mmol) was added. After a further 1 h, at −78° C., the reaction mixture was allowed to warm to room temperature, whereupon the reaction mixture was quenched with aq. ammonium chloride. The reaction mixture was then partitioned between ethyl acetate and water. The aqueous layer was then extracted with ethyl acetate (1X), and the combined organic layers were dried (Na₂SO₄), and evaporated under reduced pressure to give a pale brown solid, which was purified by silica-gel chromatography (CH₂Cl₂/5% MeOH as eluant) to give the title compound as an off white solid (0.246 g, 31%).

[0125]¹H NMR (200 MHz, CDCl₃) δ 8.54 (d, 2H), 8.27 (d, 1H), 7.40-7.00 (m, 5H), 5.30 (dd, 1H), 4.88 (s, 1H), 4.50 (t, 2H), 4.10 (t, 2H), 3.30 (dd, 1H), 3.05 (dd, 1H), 2.33 (m, 2H).

[0126] b) E-1-(3,4-Dihydro-2H-[1,3]oxazino[3,2a]indol-3-yl)-3(4-pyridyl)-prop -2-en-1-one

[0127] The product from a) (0.220 g, 6.83 mmol) was dissolved in trifluoroacetic acid (20 ml), and heated to reflux with stirring. After 4h, the reaction mixture-was allowed to cool and was evaporated under reduced pressure. The residue was then treated with aq. sodium bicarbonate and the resultant yellow suspension was extracted with CHCl₃ (3X). The combined organic layers were then dried (Na₂SO₄), and evaporated under reduced pressure to give a yellow solid. The solid was purified by silica-gel chromatography (CH₂Cl₂/5% MeOH as eluant) to give the title compound as a yellow solid (0.190 g, 92%). ¹H NMR (200 MHz, CDCl₃) δ 8.60 (d, 2H), 8.45 (d, 1H), 7.80 (d, 1H), 7.62 (d, 1H), 7.40 (d, 2H), 7.35-7.00 (m, 3H), 4.60 (t, 2H), 4.03 (t, 2H), 2.48-2.30 (m, 2H).

[0128] c) 1-(3,4-Dihydro-2H-[1,3]oxazino[3,2a]indol-10-yl)-3(4-pyridyl)propan-1-one

[0129] The product from b) (0.190 g, 0.625 mmol) was dissolved in ethanol (40 ml) and hydrogenated at atmospheric pressure in the presence of 10% PdC (0.05 g). After 17h, the reaction mixture was filtered through kieselguhr, and the filtrate evaporated under reduced pressure and dried in vacuo to give a colourless oil, which was purified by silica-gel chromatography (CH₂Cl₂/5% MeOH as eluant) to give the title compound as a pale yellow solid (0.130 g, 68%). ¹H NMR (200 MHz, CDCl₃) δ 8.48 (d, 2H), 8.32 (d, 1H), 7.32-7.05 (m, 5H), 4.50 (t, 2H), 4.08 (t, 2H), 3.20-2.95 (m, 4H), 2.35 (m, 2H).

[0130] d) 1-(3,4-Dihydro-2H-[1,3]oxazino[3,2a]indol-10-yl)-3 (1-butyl-4-piperidinyl)propan-1-one

[0131] The product from c) (0.120 g, 0.392 mmol) was dissolved in acetone (4 ml), and treated with 1-bromobutane (0.127 ml, 1.18 mmol) and heated to reflux with stirring. After 2h, and 5h, further amounts of 1-bromobutane were added, (0.127 ml, 1.18 mmol) and (0.254 ml, 2.36 mmol) respectively. Reflux was continued for a further 15h. The reaction mixture was then evaporated under reduced pressure, and dried in vacuo. The off white solid obtained was then redissolved in ethanol (20 ml) containing acetic acid (0.5 ml); platinum (IV) oxide (0.03 g) was then added and the mixture was hydrogenated at atmospheric pressure. After 24h, the reaction mixture was filtered through kieselguhr, and the filtrate evaporated under reduced pressure and dried in vacuo. The reaction mixture was then purified by silica-gel chromatography (CH₂Cl₂/10% MeOH as eluant) to give the title compound as an off white solid (0.053 g, 37%), which was converted to its oxalate salt. m.pt 156-159° C. (oxalate salt)

[0132]¹H NMR (200 MHz, CDCl₃)-free base-δ 8.32 (d, 1H), 7.30-7.05 (m, 3H), 4.55 (t, 2H), 4.12 (t, 2H), 3.20 (d, 2H), 2.88 (t, 2H), 2.60 (t, 2H), 2.45-2.18 (m, 4H), 1.95-1.50 (m, 9H), 1.35 (m, 2H), 0.97 (t, 3H).

[0133] Description 1 (intermediate for Example 1)

[0134] a) 3-Acetyl-1-methyl-1H-indole

[0135] 3-Acetyl-1H-indole (4.00 g, 0.025 mol) was dissolved in dry THF (100 ml), and treated with 80% sodium hydride (0.794 g, 0.0263 mol) with stirring under Ar. After 0.5h, methyl iodide (2.36 ml, 0.038 mol) was added. After 20h, the reaction mixture was evaporated under reduced pressure and the residue partitioned between ethyl acetate and water. The organic layer was then dried (Na₂SO₄), and evaporated under reduced pressure to give the title compound as a pale brown oil which crystallised on standing (4.20 g, 97%). ¹H NMR (250 MHz, CDCl₃), δ 8.40 (m, 1H), 7.70 (s, 1H), 7.30 (m, 3H), 3.85 (s, 3H), 2.52 (s, 3H).

[0136] b) 1-(1-Methyl-1H-indol-3-yl)-3-(4-pyridyl)-3-trimethylsilyloxypropan-1-one

[0137] 1.6M n-Butyllithium (1.19 ml, 1.90 mmol) was added to dry THF (10 ml) containing diisopropylamine (0.266 ml, 1.90 mmol) under Ar at 0° C. After 15 mins, the mixture was cooled to −78° C., and 3-acetyl-1-methyl-1H-indole (0.300 g, 1.73 mmol) in dry THF (5 ml) was added slowly. The resulting mixture was left at −78° C. for 1h, before pyridine-4-carboxaldehyde (0.165 ml, 1.73 mmol) was added. The reaction mixture was then left at −78° C. for lh, before being allowed to warm to 0° C., whereupon chlorotrimethylsilane (0.439 ml, 3.46 mmol) was added. The mixture was then allowed to warm to room temp and stirred for 1h, before being evaporated under reduced pressure and partitioned between dichloromethane and water. The organic layer was then dried (Na₂SO₄) and evaporated under reduced pressure to give a pale yellow solid which was purified by silica-gel chromatography (EtOAc as eluant) to give the title compound as a yellow solid (0.300 g, 51%).

[0138]¹H NMR (270 MHz, CDCl₃) δ 8.54 (d, 2H), 8.40 (m, 1H), 7.63 (s, 1H), 7.38 (d, 2H), 7.30 (m, 3H), 5.45 (dd, 1H), 3.80 (s, 3H), 3.30 (dd, 1H), 2.92 (dd, 1H), 0.0 (s, 9H).

[0139] Description 2 (intermediate for Example 2)

[0140] a) N-Methoxy-N-methyl-(1H-indol-3-yl)-carboxamide

[0141] Indole-3-carboxylic acid (2.50 g, 0.0155 mol) was suspended in dichloromethane (60 ml) and treated with oxalyl chloride (1.62 ml, 0.0186 mol), followed by a drop of dry DMF. The reaction mixture was then stirred at room temperature overnight, before being evaporated under reduced pressure and dried in vacuo. The product was then redissolved in dichloromethane (50 ml) and added slowly to a solution of N,O-dimethylhydroxylamine hydrochloride (1.59 g, 0.0163 mol) in dichloromethane (50 ml) containing triethylamine (4.53 ml, 0.0326 mol) under argon. The resultant mixture was then stirred at room temperature for 2h, before being washed with water, followed by aq. NaHCO₃. The organic layer was then dried (Na₂SO₄), evaporated under reduced pressure and dried in vacuo to yield the title compound as white solid (2.46 g, 78%).

[0142]¹H NMR (200 MHz, CDCl₃) δ 9.00 (s, 1H), 8.40 (m, 1H), 7.90 (d, 1H), 7.40 (m, 1H), 7.25 (m, 2H), 3.70 (s, 3H), 3.40 (s, 3H).

[0143] b) N-Methoxy-N-Methyl-(3,4-dihydro-2H-[1,3]oxazino[3,2a] indol-10-yl]carboxamide

[0144] The product from a) (2.42 g, 0.0119 mol) was suspended in chloroform (95 ml), with stirring, and treated with triethylamine (1.65 ml, 0.0119 mol) and 3-bromopropanol (2.15 ml, 0.0238 mol), followed by N-chlorosuccinimide (1.85 g, 0.0139 mol). The mixture was then stirred at room temperature for 1.5h. 1M HCl in diethyl ether (0.333 ml, 0.333 mmol), was then added. After 5 minutes, and 10 minutes, further quantities of 1M HCl (0.333 ml) were added. Upon addition of the last quantity of HCl, the temperature was observed to rise to 34° C. After a further 0.5h, the reaction mixture was washed with 10% Na₂CO₃. The organic layer was then dried (Na₂SO₄), evaporated under reduced pressure and dried in vacuo, before being redissolved in acetone (70 ml) and treated with anhydrous K₂CO₃ (3.07 g, 0.0222 mol) with stirring. The reaction mixture was then stirred overnight, filtered, and the filtrate evaporated under reduced pressure to give a brown oil, which was dried in vacuo, and then purified by silica-gel chromatography (EtOAc as eluant) to give the title compound as a colourless oil which crystallised on standing (2.60 g, 84%).

[0145]¹H NMR (200 MHz, CDCl₃) δ 7.75 (m, 1H), 7.25-7.10 (m, 3H), 4.50 (t, 2H), 4.12 (t, 2H), 3.70 (s, 3H), 3.32 (s, 3H), 2.35 (m, 2H).

[0146] c) 10-Acetyl-3,4-dihydro-2H-[1,3]oxazino[3,2a]indole

[0147] The product from b) (0.99 g, 3.81 mmol) was dissolved in dry THF, cooled to 0° C., and treated with 3.0M methylmagnesium bromide in diethyl ether (1.41 ml, 4.24 mmol) under argon, with stirring. After 20 minutes at 0° C., the reaction mixture was allowed to warm to room temperature, and after 2h, a further quantity of 3.0M methylmagnesium bromide (1.41 ml, 4.24 mmol) was added. The reaction mixture was then stirred for a further 2h, before aq. ammonium chloride was added. The reaction mixture was then partitioned between EtOAc and water. The aqueous layer was then extracted with EtOAc, and the combined organic layers were dried (Na₂SO₄) and evaporated under reduced pressure to give a red solid. Recrystalisation of the solid from EtOAc gave the title compound as a pale pink solid (0.275 g, 34%). A further quantity of the title compound was obtained by silica-gel chromatography (pentane:EtOAc,1:2 as eluant) of the filtrate from the recrystallisation, to give the title compound as a cream solid (0.152 g, 18%).

[0148]¹H NMR (250 MHz, CDCl₃) δ 8.32 (d, 1H), 7.30-7.00 (m, 3H), 4.52 (t, 2H), 4.05 (t, 2H), 2.50 (s, 3H), 2.35 (m, 2H).

[0149] 5-HT₄ Receptor Antagonist Activity

[0150] 1) Guinea Pig Colon

[0151] Male guinea-pigs, weighing 250-400 g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3 cm long, are obtained from the distal colon region. These are suspended under a 0.5 g load in isolated tissue baths containing Krebs solution bubbled with 5% CO₂ in O₂ and maintained at 37° C. In all experiments, the Krebs solution also contains methiothepin 10-7M and granisetron 10-6M to block effects at 5-HT₁, 5-HT₂ and 5-HT₃ receptors.

[0152] After construction of a simple concentration-response curve with 5-HT, using 30s contact times and a 5 min dosing cycle, a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 40-70% maximum(10-9M approx). The tissue is then alternately dosed every 15 min with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP). After obtaining consistent responses to both 5-HT and DMPP, increasing concentrations of a putative 5-HT₄ receptor antagonist are then added to the bathing solution. The effects of this compound are then determined as a percentage reduction of the contractions evoked by 5-HT or by DMPP. From this data, pIC₅₀ values are determined, being defined as the -log concentration of antagonist which reduces the contraction by 50%. A compound which reduces the response to 5-HT but not to DMPP is believed to act as a 5-HT₄ receptor antagonist.

[0153] The compound of Example 1 had a pIC₅₀ of 6.8. 

What is claimed is:
 1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: X—CO—CH₂—Z  (I) wherein X is of formula (d):

X₁—(CH₂)_(x)—X₂ forms a 5-7 membered ring wherein X₁ is O or S; X₂ is O, S, —CH₂—, NR or NRCO wherein R is hydrogen or C₁₋₆ alkyl; and x is 1,2 or 3; R₁d is hydrogen, amino, halo, C₁₋₆ alkyl, hydroxy or C₁₋₆ alkoxy; R₂ d is hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, amino or C₁₋₆ alkylthio; R₃ d is hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkoxy or amino; R₄d and R₅d are independently hydrogen or C₁₋₆ alkyl; Z is of sub-formula (h),(j) or (k):

wherein n¹ is 1,2,3 or 4; n² is 0,1,2,3 or 4; n³ is 2,3,4 or 5; q is 0,1,2 or 3; p is 0,1 or 2; m is 0,1 or 2; R₅ is hydrogen, C₁₋₁₂ alkyl, aralkyl or R₅ is (CH₂)_(z)—R₁₀ wherein z is 2 or 3 and R₁₀ is selected from cyano, hydroxyl, C₁₋₆ alkoxy, phenoxy, C(O)C₁₋₆ alkyl, COC₆H₅, -CONRL₁₁R₁₂, NR₁₁COR₁₂, SO₂NR₁₁R₁₂ or NR₁₁SO₂R₁₂ wherein R₁₁ and R₁₂ are hydrogen or C₁₋₆ alkyl; or R₅ is straight or branched chain alkylene of chain length 1-6 carbon atoms terminally substituted by aryl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered fused bicyclic heteroaryl linked through carbon, C₂₋₇ alkoxycarbonyl, or secondary or tertiary hydroxy substituted C₁₋₆ alkyl; and R₆, R₇ and R₈ are independently hydrogen or C₁₋₆ alkyl; and R₉ is hydrogen or C₁₋₁₀ alkyl; having 5-HT₄ receptor antagonist activity.
 2. A compound according to claim 1 wherein: X₁—(CH₂)_(x)—X₂ is O—(CH₂)₂—O, O—(CH₂)₃—O, O—CH₂—O, O—(CH₂)₂—NR, O—(CH₂)₂—S, O—CH₂—CONR, O—(CH₂)₂—CH₂, O—(CH₂)₃—CH₂, or O—CH₂—CH₂, wherein any of the methylene linkages are optionally mono- or di- substituted by C₁₋₆ alkyl groups; R₁ ^(d) is hydrogen or amino; R₂ ^(d) is hydrogen or halo; R₃ ^(d) is hydrogen or halo.
 3. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier.
 4. A method of treating a gastrointestinal disorder selected from the group consisting of irritable bowel syndrome, emesis, urinary incontinence associated with irritable bowel syndrome, dyspepsia and gastro-oesophageal reflux disease which comprises administering a compound according to claim
 1. 5. A method of treating atrial arrhythmia or stroke which comprises administering a compound according to claim
 1. 6. A method of treating a CNS disorder selected from the group consisting of migraine, schizophrenia, Parkinson's disease, Huntingdon's chorea and anxiety which comprises administering a compound according to claim
 1. 